U.S. Food and Drug Administration Approves FoundationOneCDx as a Companion Diagnostic for OJEMDA (Tovorafenib) to Treat the Most Common Form of Childhood Brain Tumor in Pediatric Patients
J.P. Morgan Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating
BofA Securities Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $25
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Is Breakeven Near?
Optimistic Outlook for Day One Biopharmaceuticals: Strong Sales Performance and Promising Pipeline Support Buy Rating
Needham Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $33
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}